Macropore Inc. IR-Pages
MacroPore Biosurgery Inc. english
MacroPore Biosurgery, Inc.
Ad-hoc-announcement processed and transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
MacroPore Biosurgery Centralizes Management Team in San Diego;
Accepts Resignation of Ari E. Bizimis
San Diego / Königstein, Ts, October 2, 2003. MacroPore Biosurgery, Inc.
(Frankfurt Stock Exchange: XMP) today announced that it has accepted the
resignation of Ari E. Bizimis as Chief Financial Officer and Director of
MacroPore Biosurgery, in order for him to become the Chief Executive Officer of
a privately held, life science start-up company. Mr. Bizimis will continue to
serve in an advisory capacity until his successor is named. In the interim,
Charles Galetto, Senior Vice President of Finance, will assume Mr. Bizimis’ day
to-day responsibilities.
end of ad-hoc-announcement (c)DGAP 02.10.2003
Issuer’s information/explanatory remarks concerning this ad-hoc-announcement:
Coinciding with his departure, MacroPore Biosurgery is completing its planned
process to streamline operations. This includes centralizing the management
team, closure of the Königstein office and transferring the investor relations
function to the San Diego headquarters. Stefanie Bacher, Investor Relations
Coordinator for MacroPore Biosurgery, has relocated from Königstein to San
Diego where she will continue to provide support to the Company’s extensive
international investor base. Ms. Bacher can be contacted via email at
ir@macropore.com or by calling +1-858-362- 0365.
“I would like to thank Ari for his significant contributions to MacroPore
Biosurgery and wish him success in his future endeavor,” stated Christopher J.
Calhoun, President and Chief Executive Officer for MacroPore Biosurgery. “Our
decision to centralize the management team in San Diego will help reduce
overhead and create additional operational efficiencies essential to our
continued growth. The Company has already initiated a search for a CFO with
experience in the U.S. equities market, in light of our goal to become dually
listed in the United States in the future. At the same time, the Company
remains fully committed to communicating closely with our European investors.”
MacroPore Biosurgery, Inc. is a leader in the design, development, and
production of bioresorbable polymer implants for use in a variety of surgical
applications and is pioneering advancement of regenerative medicine with
surgical therapies using adult stem cells derived from the patient’s own
adipose (fat) tissue. Some products designed for use in spine, neurosurgical,
and musculoskeletal surgeries are distributed by Medtronic, while other
products designed for soft tissue surgeries are distributed through our direct
US sales force and an international distribution network. MacroPore Biosurgery
is traded on the Frankfurt Stock Exchange in Germany under the symbol ‘XMP’.
For further information please visit the web site http://www.macropore.com .
This press release may include forward-looking statements regarding events and
trends which may affect MacroPore Biosurgery’s future operating results and
financial position. Such statements are subject to risks and uncertainties that
could cause MacroPore Biosurgery’s actual results and financial position to
differ materially. These risks and uncertainties are described (under the
heading “Risk Factors”) in our 2002 Annual Report which is available on our web
site. MacroPore Biosurgery assumes no responsibility to publicly release the
results of any revision of forward-looking statements to reflect events, trends
or circumstances after the date they are made.
——————————————————————————–
WKN: 940682; ISIN: USU553961025; Index: NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
020759 Okt 03
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found